NPS Pharmaceuticals’ President And CEO Dr. Francois Nader Receives Ernst & Young National Entrepreneur Of The Year® 2013 Award In The Life Sciences Category
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company
pioneering and delivering therapies that transform the lives of patients
with rare diseases worldwide, today announced that president and chief
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP), a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today announced that president and chief executive officer Francois Nader, M.D. has received the Ernst & Young National Entrepreneur Of The Year ® 2013 Award in the Life Sciences category. This award is regarded as the world’s most prestigious business award for entrepreneurs. Dr. Nader was honored at an awards gala, the culminating event of the EY Strategic Growth Forum ®, on November 16 in Palm Springs, California. “It’s an honor and a privilege to receive the Ernst & Young National Entrepreneur Of The Year award,” said Dr. Nader. “This wouldn’t be possible without the unwavering dedication and support of the entire NPS team. I look forward to keeping the entrepreneurial spirit alive at NPS as we continue to work to bring innovative therapeutics to patients suffering from rare diseases around the world.” Dr. Nader joined NPS in 2006 and was appointed president and chief executive officer in March 2008. He led the company’s transformation into a global commercial-stage biopharmaceutical company focused on bringing innovative treatments to patients with rare diseases. During his tenure, Dr. Nader created a values-driven culture-by-design that contributed to NPS being named as one of the top 100 companies to work for in New Jersey for two consecutive years. Earlier this year, NPS launched Gattex® (teduglutide [rDNA Origin]) for injection, its first medication approved by the U.S. Food and Drug Administration (FDA) and the European Commission. In March, Dr. Nader established NPS as a global commercial rare disease company by reacquiring the worldwide rights to its two lead drugs from Takeda GmbH. In October, the company submitted its Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its second orphan product Natpara® (recombinant human parathyroid hormone 1-84, rhPTH(1-84)) for the treatment of hypoparathyroidism.